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when and for what type of service use publicly financed health care. Methods: 
Data was retrieved from National Health Insurance Fund Administration of Hungary 
(NHIFA) and Central Statistical Office. Current study’s base was processing the last 
five years’ statistical data (2007-2012), concerning health care of third country 
citizens permanently living in Hungary. We analyzed the volume, place and medi-
cal specialty of these services. Results: In the last 5 years third country citizens 
required inpatient care 9414 times (61% in Budapest), emergency care 11776 times 
(63% in Budapest), out-patient care 72306 times (57% in Budapest). Patient accessed 
health care providers due to medical problems in the following medical fields: 
obstetrics (19%), surgery (18%), laboratory (18%), pediatrics (7%), and ophthalmol-
ogy (6%). Most of the patients are from Ukraine (42 %), China (22 %), Vietnam (11 %), 
ex-Yugoslavia (6 %) and Russia (6 %). Analysis by nationalities shows that Chinese 
population requires health care relatively few times (for instance, 2011: 5%, in 2012: 
6%) and even these are almost exclusively done in Budapest. In contrast USA citizens 
see doctors relatively often (2011: 8%, 2012: 8%), mainly in relation to diagnostics and 
curative surgery. From the neighboring non-EU states (23095 people, 31%) Ukrainian 
and (5709 people, 7%) ex-Yugoslavian citizens needed health care in the investigated 
period. Despite previous expectations, need for health care is not the characteristics 
of border regions but the capital city. ConClusions: Utilization of the Hungarian 
publicly financed health care system is significant by third country citizens. When 
planning health care capacity, this crucial fact must be taken into consideration.
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objeCtives: Many European countries regulate drug prices in order to cope with 
rising health expenditures. On the other hand, price regulation distorts incentives to 
invest in pharmaceutical R&D. This study aims at empirically assessing the impact 
of price regulation on pharmaceutical R&D expenditures. Methods: We analyze 
a sample of 20 leading pharmaceutical companies between 2000 and 2008. The 
share of sales in Europe serves as a proxy for the degree of price regulation. We 
control for other determinants of R&D such as cash flow, company size, leverage 
ratio, growth rate, and Tobin’s q. Results: Our results suggest a nonlinear rela-
tionship between European sales ratio and R&D intensity. Beyond a threshold of 
33% of sales generated in Europe, a higher presence in Europe is associated with 
lower R&D investments. ConClusions: Price regulation has a negative impact 
on pharmaceutical R&D investments. Policy makers must take long term effects 
of regulation into account.
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objeCtives: This research was designed to find out the key attribute for ben-
efit-risk assessment using swing weight method in general population, health 
authority and hospital doctors. Methods: We selected six important elements 
for each benefit and risk assessment based on previous study. The elements of 
benefit assessment consisted of disease severity, size of population affected by 
disease, clinical guidelines recommendation, comparative interventions limita-
tion, improvement of efficacy/effectiveness, improvement of quality of life. The 
attributes of risk assessment contained overall incidence of adverse events, 
overall incidence of serious adverse events, discontinuation rate due to adverse 
events, drug or food interactions, drugs of potential misuse, risk management. 
583 subjects constituted 3 groups (general population, health authority and hos-
pital doctors) were selected across the country by quota sampling method and 
performed survey to evaluate preference of each elements with the swing methods 
repeatedly. The trained interviewers assisted participant successfully completed 
survey. Results: Improvement of efficacy/effectiveness and overall incidence 
of serious adverse events were revealed as the most important attributes than 
others for benefit- risk assessment in all three groups. Health authority group 
outweighed the improvement of efficacy/effectiveness [Mean (±SD): 0.208(±0.04)] 
and overall incidence of serious adverse events [Mean (±SD): 0.220(±0.05)], while 
0.204(±0.03), 0.216(±0.04) in doctor group and 0.197(±0.04), 0.185(±0.04) in general 
population respectively. In six benefit attributes, the lowest preference score was 
clinical guidelines recommendation [0.114(±0.04)] in health authority group and 
[0.144(±0.04)] in general population while size of population affected by disease 
[0.126(±0.04)] in hospital doctor group. Among six risk elements, the lowest prefer-
ence was drugs of potential misuse showed in health authority [0.117(±0.04)] and 
in hospital doctors [0.121(±0.04)] while risk management [0.121(±0.04)] in general 
population. ConClusions: This shows that improvement of efficacy/effective-
ness among benefit attributes and overall incidence of serious adverse events 
among risk attributes are key elements for benefit-risk assessment.
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objeCtives: TLV (formerly LFN) is responsible for reimbursement decisions in 
Sweden. They regularly give temporary reimbursement with request for additional 
ject, applicable to both single and multi-company projects. Any obligatory internal 
processes should be completed in tandem. Results: Health outcomes studies, 
pharmacoeconomic evaluations, and risk sharing agreements for the access of new 
pharmaceuticals were identified as projects of high priority to implement in the 
following years. ConClusions: The steps outlined in this guidance, although not 
compulsory, will provide useful practical tips for how to go about setting up a Joint 
Working project in Catalonia (Spain), and to assist through the remainder of it. This 
guide is not a substitute for suitable regulatory or legal advice.
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objeCtives: In the context of increasing demand and expenditure for health 
services it is important to elaborate policies which maximise efficiency. 
Pharmaceuticals account for about a fifth of total health care expenditure and are 
often target of health care efficiency policies. The aim of this study is to classify 
and grade pharmaceutical supply and demand control policies across the globe 
and cluster systems by regulatory rigidity. Methods: Pharmaceutical policies and 
market data across 65 countries were researched in the literature with emphasis 
on pricing, reimbursement, dispensing, expenditure and demand control domains. 
Policies were classified by domains and graded through a multi-country expert sur-
vey for the degree of regulation. Cluster analysis helped to group countries by policy 
types. Results: Pricing policies for on-patent products (with increasing degree 
of regulation) include: free pricing, direct negotiations, value-based-pricing, cost-
plus-pricing, conditional-pricing, reference-pricing, state dictates and tenders. Cost 
control policies include: discounts, rebates, risk-sharing agreements, price-volume 
agreements, profit controls, pay-backs, claw-backs, margin cuts, price cuts, freezes, 
and tenders. Reimbursement policies include: variants of ATC5-based internal refer-
encing, variants of statutory copayments, and variants of ATC4-based internal refer-
encing. Dispensing policies were: no restrictions, indicative substitution, mandated 
or compulsory substitution. Demand controls include: educational campaigns, 
prescription aids, indicative prescription guidelines, indicative INN prescription, 
prescription monitoring, quotas, targets, predefined budgets, compulsory INN pre-
scription, mandatory electronic prescription, compulsory prescription guidelines, 
prior/posterior approvals, sanctions and incentives for target/guidelines adherence. 
Cluster analysis identified a set of countries using an intermediate regulation policy 
approach and another with a more rigid approach. These did not differ significantly 
(p: 0.20) concerning pharmaceutical expenditure as % of GDP. ConClusions: A 
variety of policies were used in recent years for controlling pharmaceutical expen-
ditures. Countries fall into two subsets based on the intensity of the regulation. 
More regulated systems do not appear to be associated with lower pharmaceutical 
expenditure.
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objeCtives: The safety profile of new drugs is usually not fully established upon 
market entry, giving cause for Europe’s comprehensive pharmacovigilance sys-
tem. A key regulatory vehicle to communicate the outcomes of pharmacovigilance 
activities is the Periodic Safety Update Report (PSUR), which summarizes a prod-
uct’s worldwide safety data and facilitates periodic assessment of its benefit-risk 
profile. We assessed the cost-effectiveness of all PSURs submitted in Europe during 
1995-2009 for biologicals, using a societal perspective. Methods: We evaluated 
two regulatory scenarios: Full Regulation (pharmacovigilance including PSURs) and 
Limited Regulation (pharmacovigilance without PSURs). We assessed the source 
of regulatory action for all urgent safety issues that were identified for biologicals 
during 1995-2009. In two out of 24 urgent safety issues (systemic spread of botu-
linum toxin and edema after use of dibotermin-alfa), PSURs were the regulatory 
instrument that identified the safety issue and we assumed these issues would 
have been discovered five years later under limited regulation. Estimates from the 
literature and Markov-chain life tables were used to calculate costs and effects 
of PSURs for biologicals. Results: The incremental cost-effectiveness ratio (ICER) 
of Full Regulation versus Limited Regulation was € 342,110 per quality-adjusted 
life year gained. Extensive sensitivity analyses indicated a low probability of the 
Full Regulation scenario being cost-effective. Only two parameters resulted in a 
more favorable ICER: a 100% risk reduction after identification of the urgent safety 
issues (base-case assumption was 25%) and a high risk (1 in 1,000 patients) of severe 
systemic spread after therapeutic use of botulinum toxin (base-case assumption 
1 in 10,000 patients). ConClusions: Regulatory cost-effectiveness analysis is a 
feasible instrument for assessing the (added) value of parts of the drug regulatory 
framework. In light of high costs of regulatory compliance, cost-effectiveness should 
be a consideration in deciding whether or not safety-related regulatory actions 
are required.
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objeCtives: The number of citizens from third countries (outside of European 
Union or stateless) permanently living in Hungary is 205 000, and annually ca. 23000 
people get permit to settle. Current study aims at exploring what group of foreigners, 
